Metraipolis › archive › dc_f0fdea27600d

The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer — Europe PMC PMID:41346024

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41346024
DOI
10.1080/07853890.2025.2597068
License (as archived)
solo-consultazione
Archived
2026-11-07T22:42:17.352Z
SHA-256 of the archived text
878caae016c179eefb0b134f284bab2a436cea38444ec4e373e32be27b0a8c44
Stable URL of this page
https://metraipolis.com/documento/dc_f0fdea27600d

How to cite

The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer — Europe PMC PMID:41346024 — Europe PMC (en), https://europepmc.org/article/MED/41346024 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f0fdea27600d (Metraipolis archive dc_f0fdea27600d, sha256 878caae016c179eefb0b134f284bab2a436cea38444ec4e373e32be27b0a8c44)
BibTeX
@misc{dcf0fdea27600d,
  title = {The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer — Europe PMC PMID:41346024},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41346024},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f0fdea27600d; sha256 878caae016c179eefb0b134f284bab2a436cea38444ec4e373e32be27b0a8c44},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41346024. Agents can read the archived copy with the MCP tool read_document.